Posted by Michael Wonder on 27 Nov 2018
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo (pegfilgrastim)
27 November 2018 - Biosimilar Ziextenzo (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications.
Sandoz today announced that the European Commission granted marketing authorization for biosimilar Ziextenzo (pegfilgrastim).
Ziextenzo is indicated to reduce the duration of neutropenia and incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes. These indications match those of the reference medicine.
